Innovative platform to develop completely human derived antibodies for the treatment of multiple cancer types.
Grid Therapeutics is an emerging bio-therapeutic company located in Durham, North Carolina. Grid’s research and development efforts are in the area of cancer therapeutics, applying an innovative platform to develop completely human derived antibodies for the treatment of multiple cancer types. Their first asset used this novel approach to produce a high affinity antibody derived from single human B cells that inhibits an essential tumor cell-protective protein, resulting in rapid tumor cell death with no known side-effects. This first-in-class antibody is being manufactured and will enter phase 1 clinical trials by the end of 2018.
Grid Therapeutics Signs Exclusive License Agreement to Develop a Novel Immuno-Oncology Antibody
Grid Therapeutics, LLC, an oncology-focused biotechnology company announced the execution of an exclusive license agreement with Duke University to develop the first human derived antibody as a targeted immunotherapy for cancer. Under the agreement, Grid has acquired the exclusive rights to all intellectual property, including relevant patents, related to Complement Factor H (CFH) antibodies as a cancer therapy, and diagnostics around CFH. Grid is based on the innovative science developed by Edward F. Patz, Jr., MD and his team at Duke University. Grid is currently developing its lead candidate for the treatment of solid tumors, and plans to begin clinical trials in cancer patients in early 2019.